Pfizer Inc Q2 2021 Earnings Call Summary - Thomson StreetEvents

Pfizer Inc Q2 2021 Earnings Call Summary

Pfizer Inc Q2 2021 Earnings Call Summary - Thomson StreetEvents
Pfizer Inc Q2 2021 Earnings Call Summary
Published Jul 28, 2021
25 pages (15209 words) — Published Jul 28, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of PFE.N earnings conference call or presentation 28-Jul-21 2:00pm GMT

  
Brief Excerpt:

...A. Overview: Delivered strong financial results. 1. 2. Even excluding direct sales and alliance revenue provided by COVID-19 vaccine, generated 10% operational revenue growth vs. 2Q20. 2Q20 was also very strong, delivering 6% operational growth for the comparable business. a. 3. Continued to accelerate the production and delivery of Pfizer-BioNTech COVID-19 vaccine. a. In collaboration with BioNTech, has now shipped more than 1b doses since last Dec. b. Prior to the pandemic, PFE produced approx. 200m doses annually across its entire vaccines portfolio. B. Growth Drivers: Pfizer-BioNTech COVID-19 Vaccine contributed $7.8b in global revenues. 1. Continues to sign agreements with governments around the world. a. b. Last week, announced that the US government has purchased an additional 200m doses, bringing the total number of doses to be supplied to the US government under existing supply agreement to 500m. This is in addition to the 500m doses that Co. agreed to provide to the US government...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Pfizer Inc
Ticker
PFE.N
Time
2:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : A few questions on the COVID vaccine, please. Firstly, a point of clarification, can I just check the upgraded 2021 sales guidance for the vaccine reflects only the doses you expect to deliver this year and not for those contracted to delivery in 2022? As it stands today, could you talk directionally about how you see 2022 COVID vaccine sales relative to this new guidance figure for 2021? Do demand for those orders you've secured require delivery of the new updated version vaccine you referenced, the COVID -- the Delta variant? And then finally, can we assume the price per dose in the most recent order from the U.S. government is equivalent to prior U.S. orders? And how does that pricing compare in the ex-U.S. contracts that you've more recently signed?

Table Of Contents

Pfizer Inc at Bank of America Global Healthcare Conference (Virtual) Transcript – 2021-09-15 – US$ 54.00 – Edited Transcript of PFE.N presentation 15-Sep-21 3:45pm GMT

Pfizer Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript – 2021-09-14 – US$ 54.00 – Edited Transcript of PFE.N presentation 14-Sep-21 2:15pm GMT

Pfizer Inc to Acquire Trillium Therapeutics Inc Call Summary – 2021-08-23 – US$ 54.00 – Edited Brief of PFE.N M&A conference call or presentation 23-Aug-21 2:00pm GMT

Pfizer Inc to Acquire Trillium Therapeutics Inc Call Transcript – 2021-08-23 – US$ 54.00 – Edited Transcript of PFE.N M&A conference call or presentation 23-Aug-21 2:00pm GMT

Pfizer Inc Q2 2021 Earnings Call Transcript – 2021-07-28 – US$ 54.00 – Edited Transcript of PFE.N earnings conference call or presentation 28-Jul-21 2:00pm GMT

Pfizer Inc at Truist Securities Life Sciences Summit (May Series) Transcript – 2021-05-05 – US$ 54.00 – Edited Transcript of PFE.N presentation 5-May-21 5:50pm GMT

Pfizer Inc Q1 2021 Earnings Call Summary – 2021-05-04 – US$ 54.00 – Edited Brief of PFE.N earnings conference call or presentation 4-May-21 2:00pm GMT

Pfizer Inc Q1 2021 Earnings Call Transcript – 2021-05-04 – US$ 54.00 – Edited Transcript of PFE.N earnings conference call or presentation 4-May-21 2:00pm GMT

Pfizer Inc Annual Shareholders Meeting Transcript – 2021-04-22 – US$ 54.00 – Edited Transcript of PFE.N shareholder or annual meeting 22-Apr-21 1:00pm GMT

Pfizer Inc Analyst and Investor Call to Review Oncology Business Summary – 2021-04-09 – US$ 54.00 – Edited Brief of PFE.N conference call or presentation 9-Apr-21 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Pfizer Inc Q2 2021 Earnings Call Summary" Jul 28, 2021. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-Pfizer-Inc-Earnings-Call-B14892865>
  
APA:
Thomson StreetEvents. (2021). Pfizer Inc Q2 2021 Earnings Call Summary Jul 28, 2021. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2021-Pfizer-Inc-Earnings-Call-B14892865>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.